Device Trial Radar · NCT03437967
Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning
Last checked: Nov 19, 2026Latest source record: Aug 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
12
Actual
Start
Aug 1, 2018
Primary completion
Jun 1, 2019
Study completion Jun 1, 2019
Sponsor
- Lead sponsor
- LiteCure LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 19, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will examine the effect of LASER photobiomodulation therapy on pain and opioid pain medication weaning on patients who are undergoing opioid pain medication weaning.
Conditions
- Chronic Pain
Interventions
LightForce EXPiDevice
LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compliance with Medical Opioid Use Reduction ProtocolTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sharp Alison DeRose Rehabilitation Center
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.